Acasti Pharma Return on Investment 2014-2024 | GRCE
Current and historical return on investment (ROI) values for Acasti Pharma (GRCE) over the last 10 years.
| Acasti Pharma ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-06-30 |
$-0.01B |
|
inf% |
| 2024-03-31 |
$-0.01B |
|
inf% |
| 2023-12-31 |
$-0.05B |
|
inf% |
| 2023-09-30 |
$-0.05B |
|
inf% |
| 2023-06-30 |
$-0.05B |
|
inf% |
| 2023-03-31 |
$-0.05B |
|
inf% |
| 2022-12-31 |
$-0.02B |
|
inf% |
| 2022-09-30 |
$-0.02B |
|
inf% |
| 2022-06-30 |
$-0.02B |
|
inf% |
| 2022-03-31 |
$-0.02B |
|
inf% |
| 2021-12-31 |
$-0.01B |
|
inf% |
| 2021-09-30 |
$-0.01B |
|
inf% |
| 2021-06-30 |
$-0.02B |
|
inf% |
| 2021-03-31 |
$-0.02B |
|
inf% |
| 2020-12-31 |
$-0.02B |
|
inf% |
| 2020-09-30 |
$-0.02B |
|
inf% |
| 2020-06-30 |
$-0.02B |
|
inf% |
| 2020-03-31 |
$-0.02B |
|
inf% |
| 2019-12-31 |
$-0.03B |
|
inf% |
| 2019-09-30 |
$-0.03B |
|
-550.00% |
| 2019-06-30 |
$-0.04B |
|
-1000.00% |
| 2019-03-31 |
$-0.04B |
|
-666.67% |
| 2018-12-31 |
$-0.03B |
$0.02B |
-413.79% |
| 2018-09-30 |
$-0.03B |
$-0.01B |
-577.78% |
| 2018-06-30 |
$-0.02B |
$0.01B |
-204.88% |
| 2018-03-31 |
$-0.02B |
$0.01B |
-122.45% |
| 2017-12-31 |
$-0.01B |
$0.01B |
-74.58% |
| 2017-09-30 |
$-0.01B |
$0.01B |
-78.26% |
| 2017-06-30 |
$-0.01B |
$0.02B |
-96.97% |
| 2017-02-28 |
$-0.01B |
$0.02B |
-177.78% |
| 2016-11-30 |
$-0.01B |
|
inf% |
| 2016-05-31 |
$-0.00B |
|
inf% |
| 2016-03-31 |
$-0.00B |
|
inf% |
| 2015-12-31 |
$-0.00B |
|
inf% |
| 2015-09-30 |
$-0.01B |
|
inf% |
| 2015-06-30 |
$-0.01B |
|
inf% |
| 2015-03-31 |
$-0.01B |
|
inf% |
| 2014-12-31 |
$-0.01B |
|
inf% |
| 2014-06-30 |
$-0.01B |
|
inf% |
| 2014-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
